Recently, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a core enterprise of Sino Biopharm (1177.HK), has completed the first shipment for the Named Patient Program (NPP) of Caring Pharma Partner in collaboration with the Greater China Cancer Foundation (hereinafter referred to as "the Foundation"). A shipment of innovative anti-cancer drugs, carrying the hope of life, was dispatched from Chia Tai Tianqing and successfully arrived in Hong Kong. This shipment includes the innovative anti-cancer drugs Anlotinib and Benmelstobart, marking the successful transition of the collaboration into the implementation phase and providing new treatment options for cancer patients in Hong Kong with urgent medical needs.

The Named Patient Program (NPP) in Hong Kong is a special mechanism for patients in urgent need of medication, allowing doctors to prescribe patients with drugs that have not yet been registered for marketing in Hong Kong, in a manner that complies with legal and ethical standards. This mechanism echoes the "1+ New Drug Registration Mechanism" and the "Good Drugs for Use in Hong Kong" initiative proposed in the 2023 Policy Address of the Hong Kong SAR Government, providing another flexible pathway for innovative drugs from the mainland to benefit Hong Kong patients sooner.

In March of this year, Chia Tai Tianqing and the Foundation signed the NPP cooperation agreement of Caring Pharma Partner in Hong Kong. According to the agreement, the two parties will provide Chia Tai Tianqing's innovative tumor treatment options to cancer patients in Hong Kong with significant unmet medical needs through the NPP. Since the signing of the agreement, the company and the Foundation have worked closely to quickly complete compliance reviews, cross-border logistics, and other tasks to ensure the efficient progress of the drug supply. This shipment is not only a fulfillment of the company's mission of "improving the quality and protecting the dignity of human life", but it also validates the unique value of the NPP model in accelerating drug accessibility.

Anlotinib and Benmelstobart are key innovative products in Sino Biopharm's anti-tumor portfolio. They have demonstrated good clinical efficacy and broad application prospects in Chinese mainland. Their combination therapy, the "Defu Combination", has refreshed data from multiple clinical trials and gained international attention. Through the NPP, eligible Hong Kong patients, as assessed by physicians, will have the opportunity to use these innovative treatment options in advance.

Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group and Honorary Co-founder of the Greater China Cancer Foundation, stated that Sino Biopharm and Chia Tai Tianqing have always taken it as their mission to promote the development and progress of China's pharmaceutical industry. We hope to bring the benefits of mainland innovation to Hong Kong patients as soon as possible through various channels, such as promoting the marketing of innovative products in Hong Kong and the NPP. In the future, we look forward to continuing our close cooperation with the Foundation to explore and initiate more collaborative opportunities, bringing new hope to cancer patients in Hong Kong.

Sino Biopharm has always integrated corporate social responsibility into its development DNA, and actively engaged in public welfare and charitable causes. The first successful shipment has laid a solid foundation for future cooperation between the company and the Foundation. It also provides more treatment options for cancer patients in Hong Kong, highlighting the deepening and innovation of medical cooperation between the mainland and Hong Kong.